**ZOOM ONLY*
How can pricing policies for new pharmaceuticals be designed to maximise long-term population health? This seminar presents a quantitative model for identifying the population health-maximising payment for new medicines, accounting for lifecycle price dynamics, the negative health system and health impacts of high pharmaceutical expenditure and the need to incentivise a robust pipeline of future medicines. I also discuss why pharmaceutical innovation can be considered a global public good, the risks that this introduces that smaller economies may ‘free-ride’ on the pull incentives provided by larger markets like the US and what this means for international pharmaceutical pricing policy design. The research provides new insights into aligning pharmaceutical pricing policy with the goal of enhancing long-run health outcomes.
Featuring:
Beth Woods, MSc, Senior Research Fellow
Centre for Health Economics
University of York
Cost: Free
IPHAM
Email